新发与恶化糖尿病患者中的胰腺癌筛查:PANDOME研究初步结果
PANDOME研究前瞻性纳入50岁及以上新发糖尿病或恶化糖尿病患者,进行磁共振成像/胆胰管成像、血液生物样本库及焦虑抑郁监测。6年间筛查625人、入组109人(新发糖尿病97例、恶化糖尿病12例)。检出1例1期胰腺导管腺癌(总体检出率0.9%),恶化糖尿病组年龄更大、糖化血红蛋白更高、体重下降更多、胰岛素需求更高,内分泌科是恶化糖尿病组主要转诊来源。
要点
- 50岁及以上新发糖尿病或恶化糖尿病患者可纳入前瞻性胰腺癌筛查研究。
- 109例入组者中检出1例1期胰腺导管腺癌,总体检出率0.9%(1/109)。
- 恶化糖尿病组较新发糖尿病组年龄更大、糖化血红蛋白更高、体重下降更多、胰岛素需求更高。
核心结论
- PANDOME研究初步结果是首次在散发性队列中报告筛查检出的早期胰腺癌。
- 研究结果支持将恶化糖尿病队列纳入高危糖尿病的前瞻性胰腺癌筛查研究。
- 内分泌科在恶化糖尿病患者的转诊中起尤其重要的作用。
研究设计与样本
- PANDOME研究为前瞻性入组研究,纳入50岁及以上新发糖尿病或恶化糖尿病患者。
- 参与者接受磁共振成像/胆胰管成像、血液生物样本库采集及焦虑/抑郁监测。
- 磁共振成像扫描评分为正常、良性异常、可疑或偶然发现,并记录血糖指标与医生转诊模式。
主要发现
- 6年间筛查625人,入组109人,其中新发糖尿病97人(89%)、恶化糖尿病12人(11%)。
- 与新高糖尿病队列相比,恶化糖尿病队列年龄更大、糖化血红蛋白更高(P=.02)、体重下降更多(P=.0038)、胰岛素需求更高(P<.0001)。
- 因可疑发现行胰腺活检4例(3.6%),在恶化糖尿病组检出1例1期胰腺导管腺癌,总体检出率0.9%(1/109)。
- 良性胰腺异常与偶然发现的检出率未显示安全信号。
- 内分泌科是恶化糖尿病队列的主要转诊来源(P<.001)。
临床怎么用
- 作者认为研究结果支持将恶化糖尿病队列纳入高危糖尿病的前瞻性胰腺癌筛查研究。
- 作者指出内分泌科在恶化糖尿病患者的转诊中起尤其重要的作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pancreatic cancer (PC) has a high mortality rate due to the lack of early-stage detection strategies and lethality of advanced stage presentations. New-onset diabetes (NOD) in individuals ≥50 years old increases the risk 6- to 8-fold, making this group a target of early detection studies. There is also evidence that deteriorating diabetes (DD) may be a risk factor. RESEARCH DESIGN AND METHODS: The study prospectively enrolled individuals ≥50 years with NOD or DD. Participants underwent magnetic resonance imaging/cholangiopancreatography, blood biobanking and anxiety/depression monitoring. Magnetic resonance imaging scans were scored as normal, benign-abnormal, suspicious, or incidental finding. Glycemic indices and physician referral patterns were captured. RESULTS: Over a 6-year period, 625 individuals were screened and 109 enrolled, 97 (89%) had NOD, and 12 (11%) had DD. Compared to the NOD cohort, the DD cohort was older, had higher hemoglobin A1c levels (P = .02), greater weight loss (P = .0038), and insulin requirements (P < .0001). Four pancreas biopsies were performed for suspicious findings (3.6%), with a stage 1 pancreatic ductal adenocarcinoma identified in the DD group, corresponding to an overall detection rate of 0.9% (1/109). The detection rates of benign pancreatic abnormalities and incidental findings revealed no safety signals. Endocrinologists were the main referral source for the DD cohort (P < .001). CONCLUSION: Results from the PANDOME study thus far include the first reported screen-detected early-stage PC in a sporadic cohort. Our findings support the inclusion of a DD cohort in prospective PC screening studies in high-risk diabetes. Endocrinologists play an especially important role in the referral of individuals with DD.
引用
- Frank RC, Shim B, Lo T, et al. Pancreatic Cancer Screening in New-onset and Deteriorating Diabetes: Preliminary Results From the PANDOME Study. J Clin Endocrinol Metab. 2025. PMID: 40439123. doi:10.1210/clinem/dgaf319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。